Robust take following exposure to vaccinia virus: Case definition and guidelines of data collection, analysis, and presentation of immunization safety data

摘要

Following a declaration by The World Health Assembly in 1980 on the worldwide eradication of smallpox [1], comprehensive smallpox vaccination programs around the world were stopped. Today, >50% of the world's population is potentially unprotected against smallpox disease [2]. Recent warnings about the possible threat of using smallpox virus as a biologic weapon [3,4] prompted a resurgence of public health vaccination programs against smallpox. In this context, and in the broader context of a need fordata comparability, as discussed in the overview paper in this volume, establishing criteria for assessing adverse events following smallpox (vaccinia) vaccination is important for clinicians administering the smallpox vaccine and appropriately treatingpatients with adverse events following immunization (AEFI), and also for scientists collecting, analyzing, and communicating data on AEFI.